{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:31:19Z","timestamp":1791865879687,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012891","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000}}],"reference-count":91,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012891.pub2","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T06:23:44Z","timestamp":1750314224000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interventions for fertility preservation in women with cancer undergoing chemotherapy"],"prefix":"10.1002","volume":"2025","author":[{"given":"Maria AJ","family":"Weterings","sequence":"additional","affiliation":[{"name":"Maastrict University Medical Center; Maastricht Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Glanville","sequence":"additional","affiliation":[{"name":"Fertility Plus; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"van Eekelen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC; Location Vrije Universiteit; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Farquhar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences; The University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"3 Supplement","key":"10.1002\/14651858.CD012891.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.fertnstert.2019.07.192","article-title":"Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols","volume":"112","author":"Balkenende","year":"2019","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cct.2017.07.009","article-title":"Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols; the study protocol of the STIM-trial","volume":"61","author":"Dahhan","year":"2017","journal-title":"Contemporary Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD012891.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdq066","article-title":"No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group","volume":"21","author":"Behringer","year":"2010","journal-title":"Annals of Oncology"},{"issue":"22","key":"10.1002\/14651858.CD012891.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial","volume":"34","author":"Demeestere","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD012891.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.2012.42.8185","article-title":"Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial","volume":"31","author":"Demeestere","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"3 SUPPL 1","key":"10.1002\/14651858.CD012891.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.fertnstert.2011.07.181","article-title":"Gonadotropin-releasing hormone analogue co-treatment does not preserve ovarian function in young women receiving cyclophosphamide-based chemotherapy: a prospective, multicenter, randomized trial","volume":"96","author":"Elgindy","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD012891.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/aog.0b013e31827374e2","article-title":"Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial","volume":"121","author":"Elgindy","year":"2013","journal-title":"Obstetrics & Gynecology"},{"issue":"10","key":"10.1002\/14651858.CD012891.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/0277-5379(91)90082-o","article-title":"Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer","volume":"27","author":"Falkson","year":"1991","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0009|cit9","first-page":"25, Abstract 90","article-title":"The effect of chemotherapy with or without GnRHA on serum hormone levels in premenopausal women with breast cancer","volume":"9","author":"Falkson","year":"1990","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD012891.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","article-title":"Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study","volume":"29","author":"Gerber","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1743-7563.2007.00089.x","article-title":"Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy","volume":"3","author":"Gilani","year":"2007","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10245330600954072","article-title":"Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)","volume":"12","author":"Giuseppe","year":"2007","journal-title":"Hematology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012891.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/jco.2008.26.15_suppl.524","article-title":"Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy","volume":"26","author":"Ismail-Khan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0014|cit14","first-page":"10","article-title":"Ovarian function preservation by GnRH agonists during chemotherapy with cyclophosphamide in breast cancer patients: a double blind randomized control trial clinical","volume":"10","author":"Karimi-Zarchi","year":"2012","journal-title":"Iranian Journal of Reproductive Medicine"},{"issue":"4 Supplement 1","key":"10.1002\/14651858.CD012891.pub2-BIB0015|cit15","first-page":"8","article-title":"Evaluation of fertility preservation with GnRH agonist in breast cancer cases treated with cyclophosphamide as an chemotherapy drug","volume":"15","author":"Karimi-Zarchi","year":"2017","journal-title":"International Journal of Reproductive BioMedicine"},{"issue":"1","key":"10.1002\/14651858.CD012891.pub2-BIB0016|cit16","first-page":"59","article-title":"Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide","volume":"35","author":"Karimi-Zarchi","year":"2014","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jama.2011.991","article-title":"Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial","volume":"306","author":"Del Mastro","year":"2011","journal-title":"JAMA"},{"issue":"26 SUPPL 1","key":"10.1002\/14651858.CD012891.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/jco.2014.32.26_suppl.105","article-title":"Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients","volume":"32","author":"Lambertini","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/annonc\/mdv335.01","article-title":"Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients","volume":"26","author":"Lambertini","year":"2015","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD012891.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"issue":"15 SUPPL","key":"10.1002\/14651858.CD012891.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2021.39.15_suppl.516","article-title":"Final analysis of the PROMISEGIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer","volume":"39","author":"Lambertini","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djab213","article-title":"Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients","volume":"114","author":"Lambertini","year":"2022","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0023|cit23","first-page":"i339","article-title":"Administration of a GnRH agonist during chemotherapy for breast cancer reduces ovarian toxicity in women aged under 40 years","volume":"31","author":"Anderson","year":"2016","journal-title":"Human Reproduction"},{"issue":"15 SUPPL 1","key":"10.1002\/14651858.CD012891.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/jco.2012.30.15_suppl.1094","article-title":"The relative value of anti-Mullerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: results from the OPTION trial","volume":"30","author":"Leonard","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012891.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","article-title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","volume":"28","author":"Leonard","year":"2017","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD012891.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10815-021-02273-3","article-title":"Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial","volume":"38","author":"Letourneau","year":"2021","journal-title":"Journal of Assisted Reproduction and Genetics"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0027|cit27","unstructured":"Letourneau J Inclusion in Cochrane review, risk of bias\/raw data [personal communication] Email to: MAJ Weterings"},{"issue":"9 SUPPL 1","key":"10.1002\/14651858.CD012891.pub2-BIB0028|cit28","first-page":"P1","article-title":"Effect of using LHRH analog during chemotherapy (CT) on premature ovarian failure and prognosis in premenopausal patients with early-stage, hormone receptor-positive breast cancer: the primary analysis of a randomized controlled phase III trial","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0029|cit29","unstructured":"Euctr BE Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-002600-33-BE"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0030|cit30","unstructured":"Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-002600-33-BE"},{"issue":"10","key":"10.1002\/14651858.CD012891.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jnci\/djy185","article-title":"Final analysis of the Prevention of Early Menopause Study (POEMS)\/SWOG Intergroup S0230","volume":"111","author":"Moore","year":"2019","journal-title":"Journal of the National Cancer Institute"},{"issue":"15 SUPPL 1","key":"10.1002\/14651858.CD012891.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"lba505","DOI":"10.1200\/jco.2014.32.18_suppl.lba505","article-title":"Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: an international intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance)","volume":"32","author":"Moore","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012891.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/JCO.2011.34.6890","article-title":"Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer","volume":"30","author":"Munster","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0035|cit35","first-page":"463","article-title":"Prevention of chemotherapy-induced ovarian failure with goserelin in premenopausal lymphoma patients","volume":"43","author":"Rabie","year":"2021","journal-title":"Bahrain Medical Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12032-013-0667-8","article-title":"Effect of leuprolide acetate on ovarian function after cyclophosphamide- doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial","volume":"30","author":"Song","year":"2013","journal-title":"Medical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012891.pub2-BIB0037|cit37","first-page":"2379","article-title":"Role of leuprorelin on ovarian function of patients with receptor-positive premenopausal breast cancer","volume":"34","author":"Sun","year":"2021","journal-title":"Pakistan Journal of Pharmaceutical Sciences"},{"issue":"9","key":"10.1002\/14651858.CD012891.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1200\/JCO.2003.04.024","article-title":"Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study","volume":"21","author":"Nystedt","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0039|cit39","unstructured":"Study author (not specified) Inclusion in Cochrane review, risk of bias\/raw data [personal communication] Email to: MAJ Weterings"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10549-009-0313-5","article-title":"Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial","volume":"117","author":"Sverrisdottir","year":"2009","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00254570","article-title":"Failure to preserve fertility in patients with Hodgkin's disease","volume":"19","author":"Waxman","year":"1987","journal-title":"Cancer Chemotherapy & Pharmacology"},{"issue":"18","key":"10.1002\/14651858.CD012891.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.7150\/jca.31859","article-title":"GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer","volume":"10","author":"Zhong","year":"2019","journal-title":"Journal of Cancer"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0043|cit43","unstructured":"Zong T Inclusion in Cochrane review, risk of bias\/raw data [personal communication] Email to: MAJ Weterings"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamaoncol.2021.6214","article-title":"Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial","volume":"8","author":"Zong","year":"2022","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1016\/j.annonc.2021.08.407","article-title":"Effects of GnRHa on ovarian function against chemotherapy-induced gonadotoxicity in premenopausal women with breast cancer in China: a prospective randomized controlled trial (EGOFACT)","volume":"32","author":"Zong","year":"2021","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.fertnstert.2007.12.044","article-title":"Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study","volume":"91","author":"Badawy","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"9","key":"10.1002\/14651858.CD012891.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1089\/jwh.2009.1552","article-title":"Ovarian function preservation by GnRH agonists during chemotherapy","volume":"18","author":"Blumenfeld","year":"2009","journal-title":"Journal of Women's Health"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/ijgc-2020-001783","article-title":"Fertility considerations prior to conservative management of gynecologic cancers","volume":"31","author":"Stewart","year":"2021","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"692834","DOI":"10.3389\/fonc.2021.692834","article-title":"A prospective study on fertility preservation in prepubertal and adolescent girls undergoing hematological stem cell transplantation","volume":"11","author":"Wikander","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"33","key":"10.1002\/14651858.CD012891.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1200\/JCO.2006.07.7081","article-title":"Fertility preservation in (breast) cancer patients: is it safe?","volume":"24","author":"Wildiers","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0051|cit51","unstructured":"Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-002600-33-BE"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0052|cit52","unstructured":"Kashyap S Protecting ovaries and fertility during chemotherapy - the PROOF trial: a randomized controlled trial of gonadotropin releasing hormone agonist (GnRHa) for fertility preservation in oncology patients https:\/\/clinicaltrials.gov\/show\/NCT00380406"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0053|cit53","unstructured":"RCT of fixed vs titrated letrozole in breast cancer patient undergoing IVF https:\/\/clinicaltrials.gov\/study\/NCT01035099"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0054|cit54","unstructured":"Administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer https:\/\/clinicaltrials.gov\/show\/NCT01530607"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0055|cit55","unstructured":"Fertility preservation in breast cancer patients (Brovale) https:\/\/www.clinicaltrials.gov\/study\/NCT02661932"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0056|cit56","unstructured":"Co-treatment with GnRH analogs on the ovarian reserve in young women treated with alkylating agents for cancer (PRESOV) https:\/\/clinicaltrials.gov\/search?cond=NCT02856048"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0057|cit57","unstructured":"Prevention of chemotherapy-induced ovarian failure with goserelin in premenopausal lymphoma patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04536467"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0058|cit58","unstructured":"Use of GnRHa during chemotherapy for fertility protection (ProFertil) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05328258"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"4","author":"Anderson","year":"2020","journal-title":"Human Reproduction Open"},{"issue":"5","key":"10.1002\/14651858.CD012891.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"954\u201368","DOI":"10.1093\/humrep\/deac035","article-title":"Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis","volume":"37","author":"Arecco","year":"2022","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0061|cit61","unstructured":"Brenner T Duggal S Nalate J Wirth SM Treatment protocols for breast cancer Available from: https:\/\/www.uptodate.com\/contents\/treatment-protocols-for-breast-cancer"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rbmo.2021.08.003","article-title":"Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis","volume":"44","author":"Chen","year":"2021","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-030-20301-6_2","article-title":"Epidemiology of breast cancer in women","volume":"1152","author":"Coughlin","year":"2019","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0064|cit64","unstructured":"Covidence systematic review software Veritas Health Innovation 2021"},{"issue":"1","key":"10.1002\/14651858.CD012891.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/AOG.0000000000000905","article-title":"Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis","volume":"126","author":"Elgindy","year":"2015","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0066|cit66","unstructured":"EndNote reference management software Clarivate 2021"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0067|cit67","unstructured":"Letrozol Available from www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/l\/letrozol"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0068|cit68","unstructured":"Tamoxifen Available from www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/t\/tamoxifen"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0069|cit69","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0070|cit70","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017) Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0071|cit71","unstructured":"Higgins JPT Eldridge S Li T Chapter 23: Including variants on randomized trials (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0072|cit72","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"626924","DOI":"10.3389\/fendo.2021.626924","article-title":"Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI)","volume":"12","author":"Ishizuka","year":"2021","journal-title":"Frontiers in Endocrinology"},{"issue":"14","key":"10.1002\/14651858.CD012891.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.3390\/ijms22147484","article-title":"Molecular mechanism and prevention strategy of chemotherapy- and radiotherapy-induced ovarian damage","volume":"22","author":"Kim","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/0974-1208.142476","article-title":"Gonadotropin-releasing hormone analogs: understanding advantages and limitations","volume":"7","author":"Kumar","year":"2014","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"24","key":"10.1002\/14651858.CD012891.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"Journal of the American Medical Association"},{"issue":"12","key":"10.1002\/14651858.CD012891.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/annonc\/mdv374","article-title":"Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies","volume":"26","author":"Lambertini","year":"2015","journal-title":"Annals of Oncology"},{"issue":"19","key":"10.1002\/14651858.CD012891.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient\u2013level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0079|cit79","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (last updated September 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3332\/ecancer.2015.504","article-title":"Ovarian stimulation in patients with breast cancer","volume":"9","author":"Mu\u00f1oz","year":"2015","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1002\/14651858.CD012891.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/rmb2.12263","article-title":"Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer","volume":"18","author":"Nakasuji","year":"2019","journal-title":"Reproductive Medicine and Biology"},{"issue":"19","key":"10.1002\/14651858.CD012891.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012891.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"494","DOI":"10.46883\/ONC.2020.3411.0494","article-title":"Supporting decision-making on fertility preservation among adolescent and young adult women with cancer","volume":"34","author":"Payne","year":"2020","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0085|cit85","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1177\/1933719118799203","article-title":"Gonadotropin-releasing hormone analogs for gonadal protection during gonadotoxic chemotherapy: a systematic review and meta-analysis","volume":"26","author":"Sofiyeva","year":"2019","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0087|cit87","unstructured":"Sonmezer M Oktay K Fertility preservation in patients undergoing gonadotoxic treatment of gonadal resection (updated 21 July 2017) UpToDate, available from https:\/\/www.uptodate.com\/contents\/fertility-preservation-in-patients-undergoing-gonadotoxic-treatment-or-gonadal-resection"},{"issue":"3","key":"10.1002\/14651858.CD012891.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5306\/wjco.v8.i3.241","article-title":"Current state and controversies in fertility preservation in women with breast cancer","volume":"8","author":"Taylan","year":"2017","journal-title":"World Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012891.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/ijms23042287","article-title":"GnRH analogues as a co-treatment to therapy in women of reproductive age with cancer and fertility preservation","volume":"23","author":"Valsamakis","year":"2022","journal-title":"Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD012891.pub2-BIB0090|cit90","unstructured":"Newsroom - fact sheet breast cancer Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"issue":"12","key":"10.1002\/14651858.CD012891.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012891","article-title":"Interventions for fertility preservation in women with cancer undergoing chemotherapy","author":"Weterings","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:02:50Z","timestamp":1776679370000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012891.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":91,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012891.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}